Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information ...
The share price of Novo Nordisk (NVO) continued to increase following approval from the U.S. Food and Drug Administration (:FDA) for its hemophilia A candidate, NovoEight. NovoEight is approved in the ...
Today, Novo Nordisk announced new phase 3 interim data from its guardian(TM)2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight(R) (turoctocog alfa), the first new rFVIII ...
Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with Novoeight ® ...
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/pp3rb2/novoeight) has announced the addition of the "NovoEight (Hemophilia A ...
Novo Nordisk today announced the company will launch Novoeight ® (Antihemophilic Factor [Recombinant]) in the United States for people living with hemophilia A. Novoeight ® offers purity, reliability, ...
"Establishing the stability of NovoEight ® up to 40°C is part of our commitment to helping people with haemophilia A to reduce the burden that this condition places on their lives," said Mads ...
The active ingredient in NovoEight is turoctocog alfa, a B-domain truncated recombinant antihemophilic factor which is produced by third generation recombinant DNA technology Novo Nordisk has launched ...
The approval of 'Novoeight' marks an important step in offering a new alternative for people with haemophilia A," Novo Nordisk Corporate Vice President Business Area Gulf, India and Egypt, Mads Bo ...
A new long term stability study has shown that haemophilia A treatment NovoEight(R) (turoctocog alfa) remains potent after three months exposure to temperatures of 40C.[1] The results were presented ...
The share price of Novo Nordisk ( NVO) continued to increase following approval from the U.S. Food and Drug Administration (FDA) for its hemophilia A candidate, NovoEight. NovoEight is approved in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results